Denmark campaign rebuilds confidence in HPV vaccination
When Eigil Rosegar Poulsen first heard about the controversy over the human papilloma virus (HPV) vaccination in Denmark, he became quite upset. Still, the debate sparked a desire to share his story.
In 2010 Eigil lost his wife, Trine, to cervical cancer—a disease caused by the HPV virus—leaving him to raise their three daughters alone. Though the WHO-recommended vaccine against the most common types of the virus was only introduced in Denmark’s child vaccination schedule in 2009, far too late for his wife to benefit, Eigil is a strong advocate for vaccination.
“It’s fantastic that you can manage a disease as serious as cervical cancer with a vaccine. But it has made me sad to see the debate,” he says. “Nobody wants to experience what we have been through. And if that can be avoided with a vaccine, I find it hard to understand why parents would opt out.”
Opting out, however, has become a big problem in Denmark. Since 2014, HPV vaccination coverage among 12-year-old Danish girls has dropped dramatically from around 90 % in previous cohorts to below 40 % due to safety concerns about the vaccine.
Reports were circulating in the media of symptoms, such as pain and tiredness, in girls who had the vaccine. An increasing volume of studies have since found these symptoms have no causal relationship to the vaccine.
WHO recommends the vaccination for all girls aged 9-14 years, as it is the most cost-effective public health measure against cervical cancer, in addition to screening. Each year, an estimated 530 000 women globally contract the disease and 266 000 die of it. Studies show that countries that introduced the vaccine have seen up to 90% reductions in HPV infections in teenage girls and young women.
Understanding parent’s concerns
To help understand why so many parents of girls around 12 years of age were postponing vaccination, the Danish Health Authority conducted an analysis in 2016. It found that nearly all parents who doubted whether to vaccinate their daughters had heard stories about the suspected side-effects, primarily through media and online.
“Even though we were putting out information about the importance of the HPV vaccines, most parents felt they were lacking the information they needed to really make informed decisions on whether to vaccinate or not,” says Bolette Søborg, senior medical consultant at the Danish Medical Authority.
A year later, the Danish Health Authority, the Danish Cancer Society and the Danish Medical Association launched the campaign, “Stop HPV, Stop Cervical Cancer,” to help build confidence in the vaccine and remind people that the risk of getting cervical cancer far outweighs the risk of adverse vaccine events. The campaign pitched articles about how to prevent cervical cancer to newspapers and lifestyle magazines throughout the country, and started a Facebook page to help answer parent questions and share stories, such as Eigil’s.
“Much of the debate about the HPV vaccine takes place on Facebook, and this is where many parents get their information. This page is a way for us to reach out to the parents and create an opportunity for an open dialogue,” says Louise Hougaard Jakobsen, consultant at the Danish Cancer Society. “We are open to all kinds of comments and questions we receive on the page and we seek to always be accommodating in our replies.”
New data reveals that less than nine months into the campaign, uptake in the number of vaccines is already increasing. During the past year, twice as many girls – nearly 31 000 girls – have started the HPV vaccination programme compared to just over 15 000 in 2016.
Sharing lessons learned across the European region
Sustaining or rebuilding public trust in vaccines is an ongoing objective of immunization programmes around the world. Through a WHO-initiated peer group started two years ago, Denmark is sharing lessons learned on HPV with countries, such as Ireland, the Netherlands and Austria.
“Several European countries have experienced declines in HPV uptake or have struggled with reaching high coverage. The WHO learning platform is the best way for these countries to support each other,” says Katrine Bach Habersaat, Technical Officer, Vaccine-preventable Disease and Immunization in the WHO Regional Office for Europe.
“Documenting and learning from Denmark’s experience is not only important to address the HPV crisis; it is critical to ensuring the success of new vaccines introduced in the future.”